Synapse Open Synapse
Biology

Karyopharm, deep in debt, to sell itself in bankruptcy

BioPharma Dive · · 2 min read

The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

Latest from BioPharma Dive